Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of BI 1358894 in borderline personality disorder
jRCT2080225372Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of bi 1358894 in borderline personality disorder (BPD) (5 arms), sponsored by Boehringer Ingelheim. Started Aug 2020; status: completed.
02
Drugs
bi 1358894
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on jRCT2080225372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225372.